Portfolio Finder

adivo

Exit

adivo is a biotech company generating therapeutic antibodies for companion animals, addressing the medical needs in dogs, with an upside potential for a future in care for other species.
Antibody selection is based on a novel fully synthetic, dog-specific phage display library that allows de-novo identification of antibodies to select a drug candidate with optimal properties.
adivo is a spin-off from MorphoSys AG, a leading European biopharmaceutical company. The team transfers an in-depth expertise in discovery and development of human therapeutic antibodies to the veterinary market.

Bind-X, formerly Dust BioSolutions, is an industrial biotechnology company with core expertise in the development, production and sale of innovative bio-based binders. The Bind-Tech technology platform is capable of solidify almost any permeable material while integrating additional functional properties. Bind-X products always increase the sustainability of Bind-X customers in the global mining, agriculture and construction industries.

Computomics is a spin-off of the University of Tübingen and the Max Planck Institute for Developmental Biology. Computomics was founded in 2012, when it became clear that a breakthrough in DNA sequencing and the scientific work of its founders would also allow seed manufacturers to use state-of-the-art bioinformatics analysis. Computomics brings customers in green and white biotechnology sustainable economic success by developing stable plant varieties that contribute to a more resource-efficient agriculture that can feed our planet.
Among the co-founders are four experienced scientists (Prof. Dr. Weigel, Prof. Dr. Huson, Prof. Dr. Rätsch, Prof. Dr. Borgwardt), who assist the co-founder and Managing Director Dr. Sebastian Schultheiss in dealing with customer inquiries. In the meantime, the Tübingen-based company employs 12 people and has founded a sales company in the USA.

PerformaNat GmbH was founded in 2015 as a spin-off of the veterinary medicine department of the Freie Universität Berlin. The first product – an animal-feed additive for use with dairy cows – was developed with the help of the EXIST Transfer of Research Grant Program of the German Federal Ministry for Economic Affairs and Energy, and it has already been successfully out-licenced. Further products are being developed.

Verovaccines is a biopharmaceutical company developing combination vaccines for animal health using a new proprietary technology. These vaccines offer several solutions for medical and industry needs in animal health: new vaccines to reduce antibiotic use, simple vaccine combinations and heat-stable vaccines for widespread use in emerging and developing countries. The technology can be used for many pathogens and is highly scalable. The company has built a portfolio of six vaccine programs, three of which achieved proof of concept in the target animal.